acelrx pharmaceuticals inc
(ACRX:NASDAQ SE Consolidated Large Cap)
acelrx pharmaceuticals inc (ACRX) Snapshot
|
Open
$7.26
|
Previous Close
$7.19
|
|
|
Day High
$7.26
|
Day Low
$6.50
|
|
|
52 Week High
05/15/13 - $7.30
|
52 Week Low
11/7/12 - $2.27
|
|
|
Market Cap
248.7M
|
Average Volume 10 Days
334.1K
|
|
|
EPS TTM
$-1.48
|
Shares Outstanding
37.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
acelrx pharmaceuticals inc (ACRX) Latest News
acelrx pharmaceuticals inc (ACRX) Related Businessweek News
No Related Businessweek News Foundacelrx pharmaceuticals inc (ACRX) Details
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company’s principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. In addition, the company’s product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
acelrx pharmaceuticals inc (ACRX) Top Compensated Officers
acelrx pharmaceuticals inc (ACRX) Key Developments
AcelRx Pharmaceuticals, Inc. appointed Badri Dasu as executive officers of the company for the year of 2013.
AcelRx Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net loss was $12,762,000 or $0.34 basic and diluted per share, compared with a net loss of $7,065,000 or $0.36 basic and diluted per share for the first quarter of 2012. Research grant revenue was $940,000 against $329,000 for the same period of last year. Loss from operations was $10,569,000 against $6,546,000 for the same period of last year. The company expects the remaining $1.2 million to be recorded as revenue over the remaining life of the grant, which terminates on January 31, 2014. The company anticipates that research and development expenses for the remaining quarters of 2013 will be substantially lower than the $9.3 million reported for the first quarter of 2013 due to lower clinical development expenses associated with NanoTab System and ARX-04 programs. These decreases in R&D will be partially offset by the work involved in the preparation of a New Drug Application for the Sufentanil NanoTab PCA System, expected to be submitted to the FDA in third quarter of 2013.
AcelRx Pharmaceuticals, Inc., Q1 2013 Earnings Call, May 08, 2013
| Recently Viewed | |||
| ACRX:US | $6.68 USD | -0.51 |  |
| Company | Last | Change | |
| No competitor information is available for ACRX. | |||
| View Industry Companies | |||
Industry Analysis
ACRX
Industry Average
| Valuation | ACRX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 88.8x |
|
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact ACELRX PHARMACEUTICALS INC, please visit www.acelrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
